GSK Drug Partner XenoPort Hit With Stock Drop Action
A XenoPort Inc. shareholder has filed a proposed class action that accuses the biopharmaceutical company of withholding information related to Horizant — a restless leg syndrome drug it was developing with...To view the full article, register now.
Already a subscriber? Click here to view full article